Mark Duerkop

We (Novasign - www.novasign.at) are currently empowering AI and mechanistic process knowledge (in so-called hybrid models) to faster screen design spaces of biopharmaceutical processes to reduce development times. Further, we are developing solutions to use the generated process models for knowledge transfer and ultimately for model predictive control.